兽用疫苗市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按疫苗类型、技术、地区、竞争细分

2022年，全球兽用疫苗市场估值达到84.4亿美元，预计在预测期内将呈现令人印象深刻的成长，到2028年实现7.28%的复合年增长率（CAGR）。该市场是重要组成部分在更广泛的兽医保健行业中，包括旨在预防和管理动物（包括伴侣动物（宠物）和牲畜）疾病的疫苗的研究、生产和分销。兽用疫苗在维护动物健康、确保粮食安全和减轻可在动物和人类之间传播的人畜共通传染病的传播方面发挥关键作用。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	84.4亿美元
2028 年市场规模	128.8亿美元
2023-2028 年复合年增长率	7.28%
成长最快的细分市场	减毒活疫苗
最大的市场	北美洲

动物疾病发生率上升

全球兽用疫苗市场受到动物传染病发生率上升的显着影响。这些疾病可能影响多种物种，包括牲畜（牛、家禽、猪）和伴侣动物（狗、猫）。此类疾病的实例包括口蹄疫、禽流感、牛呼吸道疾病和犬小病毒。动物疾病可能造成严重的经济后果。疫情爆发可能导致牲畜生产力下降、死亡率上升和贸易限制。对于农民和牲畜生产者来说，这会带来巨大的经济损失。为了减轻这些影响，开发和施用疫苗来预防这些疾病的发生和传播。 「同一个健康」的概念强调人类、动物和环境健康的相互连结。预防动物疾病不仅对动物的福祉至关重要，对公共卫生也至关重要。可以从动物传染给人类的疾病（人畜共通传染病）凸显了兽用疫苗在保护动物和人类方面的重要性。

动物福利意识不断增强

由于人们对动物福祉的认识和关注不断增强，公众对动物福利的态度发生了显着转变。宠物主人更愿意投资宠物的医疗保健，包括疫苗接种，以确保它们的健康和长寿。在畜牧业中，人们越来越认识到健康和精心照顾的动物可以提高生产力和食品安全。消费者对道德和可持续来源的动物产品的要求越来越高，这激励畜牧生产者优先考虑动物健康和福利。监管机构和动物福利组织推出了鼓励人道对待动物的准则和认证计画。这些指南通常包括透过疫苗接种来预防疾病的建议。

疫苗开发的技术进步

生物技术和基因组学的进步彻底改变了疫苗的开发。研究人员现在可以更精确地识别抗原并设计针对特定病原体的疫苗。这导致了安全性得到改善的亚单位疫苗和重组疫苗的开发。科技创新也改善了疫苗输送方法。传统的注射疫苗正在以口服疫苗和鼻内疫苗等替代品作为补充，这些疫苗可以更容易施用，并且可以减轻动物的压力。现代疫苗开发技术能够生产高效且安全的疫苗。这给兽医、宠物主人和牲畜生产者註入了信心，鼓励更多的疫苗采用。

政府措施和法规：

世界上许多国家的政府都针对动物的特定疾病实施了强制性疫苗接种计划。例如，一些地区需要对牛隻进行布鲁氏菌病疫苗接种，以防止疾病传播。牲畜疫苗接种通常与食品安全和国际贸易法规有关。政府可能要求接种某些疫苗，以确保人类消费的动物性产品的安全性并促进国际贸易。政府和公共卫生机构经常资助与动物疫苗相关的研究和开发工作。这种财政支持可以促进针对各种动物物种的新疫苗和改进疫苗的发现和开发。

主要市场挑战

监管障碍和审批流程

复杂的监管环境：兽用疫苗的开发和行销涉及复杂的监管环境。不同国家和地区有自己的疫苗审批监管机构和要求。对于疫苗製造商来说，遵守这些法规可能既耗时又昂贵。

严格的安全性和有效性标准：监管机构对兽用疫苗实施严格的安全性和有效性标准，以确保动物的福祉并防止对人类健康的潜在风险。满足这些标准通常需要进行广泛的临床前和临床测试，这可能既昂贵又耗时。

疫苗註册延迟：兽用疫苗註册和批准的延迟可能会显着减缓市场成长。製造商必须投资研究、开发和临床试验，批准过程中的任何延误都会阻碍他们及时将疫苗推向市场的能力。

市场分散化与竞争挑战

全球兽用疫苗市场分散，生产商众多，包括跨国製药公司和规模较小的专业公司。这种碎片化可能导致激烈的竞争和定价压力。农民和宠物主人等客户在兽用疫苗方面通常对价格敏感。这可能使疫苗製造商保持获利能力面临挑战，特别是在与低成本替代品竞争时。由于监管要求、分销管道和当地偏好的差异，向新兴市场扩张可能会很困难。製造商必须调整策略以适应每个资源密集型市场。

新兴疾病和抗原变异

新的、不可预测的动物疾病的出现可能为兽用疫苗市场带来重大挑战。开发针对这些疾病的疫苗通常需要广泛的研究和开发，并且上市时间可能与解决疾病爆发的紧迫性不符。一些病原体，如流感病毒，表现出抗原变异性，这意味着它们可以随着时间的推移而突变。这种变异性可能会降低现有疫苗的有效性，从而需要频繁更新和重新配製。这给疫苗製造商带来了技术和后勤方面的挑战，以保持领先于不断变化的病原体。有些疾病，特别是可以在动物和人类之间传播的人畜共通传染病，可能在野生动物中拥有宿主。由于野生动物接种疫苗很困难，透过疫苗接种来控制这些疾病可能具有挑战性。

主要市场趋势

日益关注预防性医疗保健：

全球兽用疫苗市场的一个突出趋势是越来越重视动物的预防保健。宠物主人和牲畜生产者正在认识到疫苗接种作为保护动物免受传染病侵害的主动措施的重要性。预防性医疗保健不仅可以改善动物的整体健康状况，还可以减轻与治疗患病动物相关的经济负担。

这一趋势在伴侣动物领域尤其明显，宠物主人更愿意投资常规疫苗接种，以确保宠物的健康和长寿。在畜牧业中，预防性疫苗接种正成为维持牛群健康和生产力的标准做法。

疫苗技术的进步：

疫苗技术的进步正在推动兽用疫苗市场的创新。这些进步涵盖了疫苗开发、生产和管理的各个方面：研究人员正在探索新的疫苗平台，例如 DNA 疫苗、重组疫苗和病毒样颗粒疫苗。这些平台提供了更高的安全性、有效性和生产简易性。改进的佐剂和输送系统正在提高疫苗的有效性并减少加强注射的需要。这些创新使宠物主人和牲畜生产者更方便地接种疫苗。基因组学和抗原发现的进步使得能够开发出针对特定病原体提供更好保护的标靶和客製化疫苗。这一趋势对于应对新出现和不断演变的疾病尤其重要。

全球化与市场扩张：

在全球化和动物产品贸易增加的推动下，全球兽用疫苗市场正经历显着扩张。几个相关趋势促成了这种成长：

亚洲、拉丁美洲和非洲的新兴市场对兽用疫苗的需求正在增加。随着这些地区的经济发展和城市化，对动物性蛋白质和宠物的需求不断增加，从而推动了对疫苗的需求。动物和动物产品的国际贸易需要遵守国际健康和安全标准。这反过来又增加了对疫苗的需求，以确保运输途中动物的健康和安全。疫苗製造商正在建立合作和伙伴关係，以扩大其全球影响力并进入新市场。这包括合资企业、许可协议和分销合作伙伴关係。

细分市场洞察

疫苗类型见解

根据疫苗类型类别，牲畜疫苗细分市场将在 2022 年成为全球兽用疫苗市场的主导者。牲畜疫苗细分市场在全球兽用疫苗市场中的主导地位可归因于与类型相关的多个因素畜牧业中使用的疫苗。牲畜疫苗专门用于满足各种农场动物（包括牛、猪、家禽、绵羊和山羊）的健康和疾病预防需求。

牲畜疫苗涵盖针对不同牲畜品种和特定疾病的多种疫苗类型。这种多样性包括针对口蹄疫、牛呼吸道疾病、禽流感、猪圆环病毒相关疾病等疾病的疫苗。

畜牧业非常重视预防性医疗保健，以维持牛群健康和生产力。疫苗接种是这种方法的基石。牲畜疫苗的配製是为了保护动物免受可能因产量减少、死亡率增加和贸易限製而造成重大经济损失的疾病。全球牲畜数量庞大，饲养了数十亿头动物来生产肉类、牛奶和其他产品。例如，全球有超过 15 亿头牛和近 250 亿隻鸡。如此庞大的人口对疫苗产生了巨大的需求，以保护这些动物免受传染病的侵害。畜牧业是全球农业的重要组成部分，为许多国家的粮食安全和经济稳定做出了贡献。因此，牲畜疾病爆发的经济影响可能是巨大的，从而推动了疫苗接种的需求。牲畜很容易感染一系列传染病，其中一些具有高度传染性，可以在牛群或羊群中迅速传播。控制和预防这些疾病通常需要采取多方面的方法，其中疫苗接种是关键组成部分。一些牲畜疾病可能具有人畜共患病的可能性，这意味着它们可以从动物传播给人类。透过疫苗接种来预防这些疾病不仅对动物健康至关重要，而且对公共卫生也至关重要。预计这些因素将推动该领域的成长。

技术洞察

减毒活疫苗领域预计将在预测期内快速成长。减毒活疫苗是一类含有其针对的病原体的弱化或修饰形式的疫苗。与其他类型的疫苗相比，减毒活疫苗通常能提供更强、更持久的免疫反应。这是因为它们非常模仿自然感染，刺激体液（抗体）和细胞免疫。

在许多情况下，减毒活疫苗需要较少的剂量即可获得持久的免疫力。这在兽医环境中特别有利，因为施用多次剂量可能具有挑战性，特别是对于农场动物。减毒活疫苗在根除或控制多种毁灭性动物疾病方面发挥了至关重要的作用。例如，使用减毒活疫苗有助于控制牛瘟和猪伪狂犬病等疾病。一旦疾病爆发，可以迅速部署减毒活疫苗来控制疾病的传播并保护脆弱的动物族群。减毒活疫苗通常可以针对病原体的多种菌株或变种提供交叉保护。这在处理表现出抗原变异的病原体时特别有价值。减毒活疫苗可用于预防多种病毒和细菌性疾病，使其成为兽医和牲畜生产者的多功能工具。这些因素共同促进了该细分市场的成长。

区域洞察

2022年，北美成为全球兽用疫苗市场的主导者，以价值计算，占据最大的市场份额。美国拥有大量宠物，包括狗、猫和马，导致对伴侣动物疫苗的大量需求。北美畜牧业发达，牛肉和乳製品产量高。这导致对牲畜疫苗的大量需求，以维持畜群健康和生产力。该地区拥有领先的兽医研究机构和疫苗製造商，推动了新疫苗技术的创新和开发。

亚太市场可望成为成长最快的市场，在预测期内为兽用疫苗厂商提供利润丰厚的成长机会。因素随着亚太地区国家快速都市化和经济发展，对动物性蛋白质的需求不断增加，导致畜牧业不断发展。中国和印度等国家的宠物数量迅速增加，宠物主人对宠物医疗保健（包括疫苗接种）的投资意识和意愿增强。一些亚太国家面临畜禽地方病的持续挑战。政府和农民越来越多地利用疫苗作为疾病控製手段，以确保粮食安全。该地区对兽医保健基础设施的投资正在增加，包括疫苗接种计划和新疫苗的研发。一些亚太地区政府正在实施促进动物性产品生产的政策，其中包括推广疫苗接种以改善牲畜健康。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况

第 4 章：市场驱动因素、挑战、趋势概述

第 5 章：客户之声

第 6 章：全球兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疫苗类型（牲畜疫苗、伴侣动物疫苗）
  • 依技术分类（减毒活疫苗、不活化疫苗、类毒素疫苗、重组疫苗、其他）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 7 章：北美兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按疫苗类型
  • 依技术
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 8 章：欧洲兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按疫苗类型
  • 依技术
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 9 章：亚太地区兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按疫苗类型
  • 依技术
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 10 章：南美洲兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按疫苗类型
  • 依技术
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲兽用疫苗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按疫苗类型
  • 依技术
• MEA：国家分析
  • 南非兽用疫苗
  • 沙乌地阿拉伯兽用疫苗
  • 阿联酋兽用疫苗

第 12 章：市场动态

• 驱动因素与挑战

第 13 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 14 章：全球兽用疫苗市场：SWOT 分析

第15章：竞争格局

• 商业概览
• 技术产品
• 最近的发展
• 主要人员
• SWOT分析
  • Zoetis Inc.
  • Merck & Co. Inc.
  • Virbac
  • Hester Biosciences Limited
  • Elanco Animal Health
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • HIPRA

第 16 章：策略建议

第 17 章：关于我们与免责声明

In 2022, the Global Veterinary Vaccines Market reached a valuation of USD 8.44 billion, and it is expected to demonstrate impressive growth in the forecasted period, achieving a Compound Annual Growth Rate (CAGR) of 7.28% through 2028. This market is an essential component within the broader veterinary healthcare industry, encompassing the research, production, and distribution of vaccines designed to prevent and manage diseases in animals, including both companion animals (pets) and livestock. Veterinary vaccines play a pivotal role in preserving animal health, ensuring food security, and mitigating the spread of zoonotic diseases, which can be transmitted between animals and humans.

The population of companion animals, including dogs, cats, and horses, is continually increasing on a global scale. Pet owners are increasingly willing to invest in healthcare for their animals, including vaccinations, to safeguard their well-being and extend their lifespan.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 8.44 Billion
Market Size 2028	USD 12.88 Billion
CAGR 2023-2028	7.28%
Fastest Growing Segment	Live Atteneuated Vaccines
Largest Market	North America

Rising Incidence of Animal Diseases

The global veterinary vaccine market is significantly influenced by the increasing incidence of infectious diseases among animals. These diseases can affect various species, including livestock (cattle, poultry, swine) and companion animals (dogs, cats). Examples of such diseases include foot-and-mouth disease, avian influenza, bovine respiratory disease, and canine parvovirus. Animal diseases can have severe economic consequences. Outbreaks can lead to reduced livestock productivity, increased mortality rates, and trade restrictions. For farmers and livestock producers, this translates into substantial financial losses. To mitigate these impacts, vaccines are developed and administered to prevent the occurrence and spread of these diseases. The concept of One Health emphasizes the interconnectedness of human, animal, and environmental health. Preventing animal diseases is not only essential for the well-being of animals but also for public health. Diseases that can jump from animals to humans (zoonoses) highlight the importance of veterinary vaccines in safeguarding both animal and human populations.

Growing Awareness of Animal Welfare

There is a notable shift in public attitudes toward animal welfare, driven by increased awareness and concern for the well-being of animals. Pet owners are more willing to invest in healthcare for their pets, including vaccinations, to ensure their health and longevity. In the livestock industry, there is a growing recognition that healthy and well-cared-for animals lead to higher productivity and food safety. Consumers are increasingly demanding ethically and sustainably sourced animal products, which incentivizes livestock producers to prioritize animal health and welfare. Regulatory bodies and animal welfare organizations have introduced guidelines and certification programs that encourage the humane treatment of animals. These guidelines often include recommendations for disease prevention through vaccination.

Technological Advancements in Vaccine Development

Advances in biotechnology and genomics have revolutionized vaccine development. Researchers can now identify antigens more precisely and design vaccines tailored to specific pathogens. This has led to the development of subunit vaccines and recombinant vaccines with improved safety profiles. Technological innovations have also improved vaccine delivery methods. Traditional injectable vaccines are being supplemented with alternatives such as oral vaccines and intranasal vaccines, which can be administered more easily and with reduced stress for animals. Modern vaccine development techniques enable the creation of vaccines that are both highly efficacious and safe. This instills confidence in veterinarians, pet owners, and livestock producers, encouraging greater vaccine adoption.

Government Initiatives and Regulations:

Many governments around the world have implemented mandatory vaccination programs for specific diseases in animals. For example, bovine brucellosis vaccination is required in cattle in some regions to prevent the disease's spread. Vaccination of livestock is often tied to food safety and international trade regulations. Governments may require certain vaccinations to ensure the safety of animal-derived products for human consumption and to facilitate international trade. Governments and public health agencies often fund research and development efforts related to animal vaccines. This financial support can lead to the discovery and development of new and improved vaccines for various animal species.

Key Market Challenges

Regulatory Hurdles and Approval Processes

Complex Regulatory Landscape: Developing and marketing veterinary vaccines involves navigating a complex regulatory landscape. Different countries and regions have their own regulatory agencies and requirements for vaccine approval. Complying with these regulations can be time-consuming and costly for vaccine manufacturers.

Stringent Safety and Efficacy Standards: Regulatory agencies impose stringent safety and efficacy standards on veterinary vaccines to ensure the well-being of animals and prevent potential risks to human health. Meeting these standards often requires extensive preclinical and clinical testing, which can be expensive and time intensive.

Vaccine Registration Delays: Delays in the registration and approval of veterinary vaccines can significantly slow down market growth. Manufacturers must invest in research, development, and clinical trials, and any delays in the approval process can hinder their ability to bring vaccines to market in a timely manner.

Market Fragmentation and Competitive Challenges

The global veterinary vaccine market is fragmented, with many manufacturers, including both multinational pharmaceutical companies and smaller, specialized firms. This fragmentation can lead to intense competition and pricing pressures. Customers, such as farmers and pet owners, are often price-sensitive when it comes to veterinary vaccines. This can make it challenging for vaccine manufacturers to maintain profitability, particularly when competing with lower-cost alternatives. Expanding into emerging markets can be difficult due to variations in regulatory requirements, distribution channels, and local preferences. Manufacturers must adapt their strategies to suit each market, which can be resource intensive.

Emerging Diseases and Antigenic Variability

The emergence of new and unpredictable animal diseases can pose significant challenges to the veterinary vaccine market. Developing vaccines for these diseases often requires extensive research and development, and the timeline to market may not align with the urgency of addressing disease outbreaks. Some pathogens, like influenza viruses, exhibit antigenic variability, meaning they can mutate over time. This variability can render existing vaccines less effective, necessitating frequent updates and reformulations. This poses technical and logistical challenges for vaccine manufacturers to stay ahead of evolving pathogens. Some diseases, particularly zoonotic diseases that can be transmitted between animals and humans, may have reservoir hosts in wildlife. Controlling these diseases through vaccination can be challenging due to the difficulty of vaccinating wild animals.

Key Market Trends

Increasing Focus on Preventive Healthcare:

One prominent trend in the global veterinary vaccine market is the increasing emphasis on preventive healthcare for animals. Pet owners and livestock producers are recognizing the importance of vaccination as a proactive measure to protect animals from infectious diseases. Preventive healthcare not only improves the overall well-being of animals but also reduces the economic burden associated with treating sick animals.

This trend is particularly evident in the companion animal sector, where pet owners are more willing to invest in routine vaccinations to ensure the health and longevity of their pets. In the livestock industry, preventive vaccination is becoming standard practice to maintain herd health and productivity.

Advancements in Vaccine Technology:

Advances in vaccine technology are driving innovation in the veterinary vaccine market. These advancements encompass various aspects of vaccine development, production, and administration: Researchers are exploring new vaccine platforms, such as DNA vaccines, recombinant vaccines, and virus-like particle vaccines. These platforms offer improved safety, efficacy, and ease of production. Improved adjuvants and delivery systems are enhancing vaccine effectiveness and reducing the need for booster shots. These innovations are making vaccines more convenient for both pet owners and livestock producers. Advances in genomics and antigen discovery are enabling the development of targeted and customized vaccines that provide better protection against specific pathogens. This trend is particularly relevant for addressing emerging and evolving diseases.

Globalization and Market Expansion:

The global veterinary vaccine market is experiencing significant expansion, driven by globalization and increased trade in animal products. Several related trends contribute to this growth:

Emerging markets in Asia, Latin America, and Africa are witnessing a rise in demand for veterinary vaccines. As these regions undergo economic development and urbanization, the demand for animal protein and pet ownership is increasing, driving the need for vaccines. The international trade of animals and animal products necessitates compliance with international health and safety standards. This, in turn, boosts the demand for vaccines to ensure the health and safety of animals in transit. Vaccine manufacturers are forming collaborations and partnerships to expand their global presence and access new markets. This includes joint ventures, licensing agreements, and distribution partnerships.

Segmental Insights

Vaccine Type Insights

Based on the category of Vaccine Type, the livestock vaccine segment emerged as the dominant player in the global market for Veterinary Vaccines in 2022. The dominance of the livestock vaccine segment in the global veterinary vaccine market can be attributed to several factors related to the types of vaccines used in the livestock industry. Livestock vaccines are specifically designed to address the health and disease prevention needs of various farm animals, including cattle, swine, poultry, sheep, and goats.

The Livestock vaccines encompass a wide range of vaccine types tailored to different livestock species and specific diseases. This diversity includes vaccines for diseases like foot-and-mouth disease, bovine respiratory disease, avian influenza, porcine circovirus-associated disease, and many others.

The livestock industry places a strong emphasis on preventive healthcare to maintain herd health and productivity. Vaccination is a cornerstone of this approach. Livestock vaccines are formulated to protect animals from diseases that can cause substantial economic losses through reduced production, increased mortality, and trade restrictions. The global livestock population is immense, with billions of animals raised for meat, milk, and other products. For example, there are over 1.5 billion cattle and nearly 25 billion chickens globally. Such large populations create a significant demand for vaccines to protect these animals from infectious diseases. Livestock farming is a vital component of the global agriculture industry, contributing to food security and economic stability in many countries. Consequently, the economic impact of disease outbreaks in livestock can be substantial, driving the need for vaccination. Livestock can be vulnerable to a range of infectious diseases, some of which are highly contagious and can spread rapidly within herds or flocks. Controlling and preventing these diseases often requires a multifaceted approach, with vaccination being a critical component. Some livestock diseases can have zoonotic potential, meaning they can be transmitted from animals to humans. Preventing these diseases through vaccination is not only essential for animal health but also for public health. These factors are expected to drive the growth of this segment.

Technology Insights

The live attenuated vaccines segment is projected to experience rapid growth during the forecast period. Live attenuated vaccines are a category of vaccines that contain weakened or modified forms of the pathogen they target. Live attenuated vaccines often provide a stronger and more sustained immune response compared to other types of vaccines. This is because they closely mimic natural infections, stimulating both humoral (antibody) and cellular immunity.

In many cases, live attenuated vaccines require fewer doses to confer long-lasting immunity. This is particularly advantageous in veterinary settings where administering multiple doses can be challenging, especially for farm animals. Live attenuated vaccines have played a crucial role in eradicating or controlling several devastating animal diseases. For example, the use of live attenuated vaccines has been instrumental in controlling diseases like rinderpest in cattle and pseudorabies in pigs. In the event of disease outbreaks, live attenuated vaccines can be rapidly deployed to control the spread of the disease and protect vulnerable populations of animals. Live attenuated vaccines often provide cross-protection against multiple strains or variants of a pathogen. This is particularly valuable when dealing with pathogens that exhibit antigenic variation. Live attenuated vaccines can be used to protect against a wide range of viral and bacterial diseases, making them versatile tools for veterinarians and livestock producers. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Veterinary Vaccines market in 2022, holding the largest market share in terms of value. The United States has a significant population of pets, including dogs, cats, and horses, leading to a substantial demand for companion animal vaccines. North America boasts a well-developed livestock industry, with high-quality beef and dairy production. This has led to a substantial need for livestock vaccines to maintain herd health and productivity. The region is home to leading veterinary research institutions and vaccine manufacturers, driving innovation and the development of new vaccine technologies.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Veterinary Vaccines players during the forecast period. Factors As APAC countries undergo rapid urbanization and economic development, there is an increasing demand for animal protein, leading to a growing livestock industry. Countries like China and India have rapidly expanding pet populations, with pet owners showing greater awareness of and willingness to invest in pet healthcare, including vaccinations. Some APAC countries face ongoing challenges with endemic diseases in livestock and poultry. Governments and farmers are increasingly turning to vaccines as a means of disease control to ensure food security. The region is witnessing increased investment in veterinary healthcare infrastructure, including vaccination programs and research and development of new vaccines. Some APAC governments are implementing policies to boost the production of animal-derived products, which includes promoting vaccination to improve livestock health.

Key Market Players

• Zoetis Inc.

• Merck & Co. Inc.

• Virbac SA

• Hester Biosciences Limited

• Elanco Animal Health

• Boehringer Ingelheim International GmbH

• Ceva Sante Animale

• Phibro Animal Health Corporation

• HIPRA

Report Scope:

In this report, the Global Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Vaccines Market, By Vaccine Type:

• Livestock Vaccine
• Companion Animal Vaccine

Veterinary Vaccines Market, By Technology:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Other

Veterinary Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Vaccines Market.

Available Customizations:

• Global Veterinary Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries

4. Overview of Market Drivers, Challenges, Trends

5. Voice of Customer

6. Global Veterinary Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type (Livestock Vaccine, Companion Animal Vaccine)
  • 6.2.2. By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other)
  • 6.2.3. By Region
  • 6.2.4. By Company (2022)
• 6.3. Market Map

7. North America Veterinary Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Veterinary Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Technology
  • 7.3.2. Canada Veterinary Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Technology
  • 7.3.3. Mexico Veterinary Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Technology

8. Europe Veterinary Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Technology
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Veterinary Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Technology
  • 8.3.2. United Kingdom Veterinary Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Technology
  • 8.3.3. Italy Veterinary Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Technology
  • 8.3.4. France Veterinary Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Technology
  • 8.3.5. Spain Veterinary Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Technology

9. Asia-Pacific Veterinary Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Technology
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Veterinary Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Technology
  • 9.3.2. India Veterinary Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Technology
  • 9.3.3. Japan Veterinary Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Technology
  • 9.3.4. South Korea Veterinary Vaccines Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vaccine Type
      • 9.3.4.2.2. By Technology
  • 9.3.5. Australia Veterinary Vaccines Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vaccine Type
      • 9.3.5.2.2. By Technology

10. South America Veterinary Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Technology
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Technology
  • 10.3.2. Argentina Veterinary Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Technology
  • 10.3.3. Colombia Veterinary Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Technology

11. Middle East and Africa Veterinary Vaccines Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vaccine Type
  • 11.2.2. By Technology
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Veterinary Vaccines Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vaccine Type
      • 11.3.1.2.2. By Technology
  • 11.3.2. Saudi Arabia Veterinary Vaccines Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vaccine Type
      • 11.3.2.2.2. By Technology
  • 11.3.3. UAE Veterinary Vaccines Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vaccine Type
      • 11.3.3.2.2. By Technology

12. Market Dynamics

• 12.1. Drivers & Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Veterinary Vaccines Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Technology Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Zoetis Inc.
  • 15.5.2. Merck & Co. Inc.
  • 15.5.3. Virbac
  • 15.5.4. Hester Biosciences Limited
  • 15.5.5. Elanco Animal Health
  • 15.5.6. Boehringer Ingelheim International GmbH
  • 15.5.7. Ceva Sante Animale
  • 15.5.8. Phibro Animal Health Corporation
  • 15.5.9. HIPRA

16. Strategic Recommendations

17. About Us & Disclaimer